Randomized trials have failed to support a survival benefit with maintenance rituximab but ... for patients with relapsed or refractory follicular lymphoma, and these patients should be treated ...

Follicular lymphoma is a diverse disease ... The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline ...

In the era of rituximab, whether ASCT is needed in the treatment of follicular lymphoma remains a valid question. In the retrospective GELA study, both rituximab and ASCT had a benefit on patients ...

While not FDA approved, rituximab combined with lenalidomide (Revlimid) has emerged as a potential chemotherapy-free first-line option for advanced follicular lymphoma. Results from the RELEVANCE ...

"At that time this was very specific to patients who had follicular lymphoma and were receiving as first line of treatment R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine ...

Progression within 6 months of completing rituximab maintenance therapy or progression before the next scheduled dose of rituximab; Progression within 6 months of completing a full course of ...

Branded as Rituxan Hycela, subcutaneous rituximab is administered in combination with hyaluronidase human and is approved for adults with follicular lymphoma, diffuse large B-cell lymphoma and ...